golin link was a false trail laid from China. Nature, however, rejected a submission from another key scientific dissident that showed how all four papers primarily used samples from the same batch of pangolins and that key data was inaccurately reported in two of these papers. Richard Ebright, a bio-security expert and professor of chemical biology at Rutgers University, argues that such tolerance of “material omissions and material misstatements” expose a massive issue. “Nature and The Lancet played important roles in enabling, encouraging, and enforcing the false narrative that science evidence indicates Sars-CoV-2 had a natural-spillover origin points and the false narrative that this was the scientific consensus”.
Or as another well-placed observer put it: “The game seems to be for Nature and The Lancet to rush non-peer revised correspondences to set the tone and then delay critical papers and responses.”
But why would they do this? This is where things become even murkier. Allegations swirl that it was not down to editorial misjudgement, but something more sinister: a desire to appease China for commercial reasons. The Financial Times revealed four years ago that debt-laden Springer Nature, the German group that publishes Nature, was blocking access in China to hundreds of academic articles mentioning subjects deemed sensitive by Beijing such as Hong Kong, Taiwan or Tibet. China is also spending lavishly around the world to win supremacy in science — which includes becoming the biggest national sponsor of open access journals published by both Springer Nature and Elsevier, owner of The Lancet.
One source estimated that 49 sponsorship agreements between Springer Nature and Chinese institutions were worth at least $10m last year. These deals cover the publishing fees authors would normally pay in such journals, so they smooth the path for Chinese authors while creating a dependency culture. They have worked well for both sides: they offer the publishers access to the surging Chinese market and its well-resourced universities, while offering international recognition and status in return. But we know President Xi Jinping demands compliance with his world view, even from foreign-owned companies — and especially on an issue as sensitive as his nation’s possible role in unleashing a global catastrophe.
Critics fear these corporate links to China compromise output and distort agendas. “Scientific publishing has become a highly politicised business,” argues Petrovksy. “Clearly there needs to be an international investigation launched into the role of scientific publishers, their increasingly powerful influence as the major publishing houses buy out many of the smaller independent journals, together with their growing politicisation and susceptibility to overt influence. We need to examine what impact this may have had in the pandemic and what impact it could have on science in the future.”
Certainly it is valid to ask where was the real conspiracy in this tawdry saga that has stained so many reputations?
















